Ribometrix
Matt Smola has worked in the field of RNA Biology for over a decade. Matt began their career in 2007 as an Undergraduate Research Assistant at Miami University. In 2010, they joined the University of North Carolina at Chapel Hill as a Graduate Research Assistant. In 2016, they became a Postdoctoral Scholar at Novartis Institutes for BioMedical Research (NIBR), where their work focused on technology and assay development. Matt then joined Ribometrix Inc. in 2018, where they held the roles of Associate Director of RNA Biology, Senior Scientist I, and Scientist II.
Matt Smola obtained a Bachelor of Science (BS) in Biochemistry from Miami University in 2010. Matt then went on to pursue a Doctor of Philosophy (PhD) in Chemical Biology from the University of North Carolina at Chapel Hill, which they completed in 2015. In 2013, they also obtained a Research Mentoring certification from the University of North Carolina at Chapel Hill.
Ribometrix
Ribometrix, headquartered in Durham, North Carolina, is a biotechnology company leveraging world-leading expertise in three-dimensional structural analysis of RNA as the foundation of its proprietary drug discovery platform. This platform enables the identification of novel small molecules that modulate the function of RNA and proteins associated with human disease. Ribometrix’ value creation strategy is built around developing an internal pipeline of drug candidates and partnerships with the leading biopharmaceutical companies. Ribometrix is backed by a syndicate of blue-chip venture investors.